These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 38473419)

  • 1. The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives.
    Żak K; Satora M; Skrabalak I; Tarkowski R; Ostrowska-Leśko M; Bobiński M
    Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.
    Matsui J; Funahashi Y; Uenaka T; Watanabe T; Tsuruoka A; Asada M
    Clin Cancer Res; 2008 Sep; 14(17):5459-65. PubMed ID: 18765537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
    Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
    J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
    He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
    J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis.
    Matsumoto M; Roufail S; Inder R; Caesar C; Karnezis T; Shayan R; Farnsworth RH; Sato T; Achen MG; Mann GB; Stacker SA
    Clin Exp Metastasis; 2013 Aug; 30(6):819-32. PubMed ID: 23591595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007419. PubMed ID: 30325017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant.
    Wimberger P; Gerber MJ; Pfisterer J; Erdmann K; Füssel S; Link T; du Bois A; Kommoss S; Heitz F; Sehouli J; Kimmig R; de Gregorio N; Schmalfeldt B; Park-Simon TW; Baumann K; Hilpert F; Grube M; Schröder W; Burges A; Belau A; Hanker L; Kuhlmann JD
    Clin Cancer Res; 2022 Nov; 28(21):4660-4668. PubMed ID: 36001383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients.
    Ding Y; Oliveira-Ferrer L; Vettorazzi E; Legler K; Milde-Langosch K; Woelber L; Jaeger A; Prieske K; Mueller V; Schmalfeldt B; Kuerti S
    PLoS One; 2022; 17(6):e0269680. PubMed ID: 35687576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.
    Bock F; Onderka J; Dietrich T; Bachmann B; Kruse FE; Paschke M; Zahn G; Cursiefen C
    Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2545-52. PubMed ID: 17525183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Akt-activated endothelium constitutes the niche for residual disease and resistance to bevacizumab in ovarian cancer.
    Guerrouahen BS; Pasquier J; Kaoud NA; Maleki M; Beauchamp MC; Yasmeen A; Ghiabi P; Lis R; Vidal F; Saleh A; Gotlieb WH; Rafii S; Rafii A
    Mol Cancer Ther; 2014 Dec; 13(12):3123-36. PubMed ID: 25319392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.
    Liu H; Yang Y; Xiao J; Yang S; Liu Y; Kang W; Li X; Zhang F
    Microvasc Res; 2014 May; 93():1-8. PubMed ID: 24603190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases.
    Jeong HS; Jones D; Liao S; Wattson DA; Cui CH; Duda DG; Willett CG; Jain RK; Padera TP
    J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26063793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of antiangiogenic therapies for ovarian cancer.
    Markowska A; Lubin J; Madry R; Markowska J
    Eur J Gynaecol Oncol; 2013; 34(4):303-6. PubMed ID: 24020134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
    Al Wadi K; Ghatage P
    Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPARC suppresses lymph node metastasis by regulating the expression of VEGFs in ovarian carcinoma.
    Peng F; Zhong Y; Liu Y; Zhang Y; Xie Y; Lu Y; Zhang X; Li D
    Int J Oncol; 2017 Dec; 51(6):1920-1928. PubMed ID: 29075785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
    van der Bilt AR; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Schröder CP; Pot L; Kosterink JG; van der Zee AG; Lub-de Hooge MN; de Jong S; de Vries EG; Reyners AK
    Clin Cancer Res; 2012 Nov; 18(22):6306-14. PubMed ID: 23014526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
    Kim SI; Lee EJ; Lee M; Chung H; Kim JW; Park NH; Song YS; Kim HS
    Int J Gynecol Cancer; 2020 Dec; 30(12):1943-1950. PubMed ID: 33055266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.